Bain Capital Specialty Finance, Inc.
BCSF NYSE Financials FY2020–FY2025
Last close · Oct 23, 2026
$10.07
1.7%What Bain Capital Specialty Finance, Inc. does
No business description yet.
- Legal name
- Bain Capital Specialty Finance, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 27, 2026
- Accession · CIK
- 0001193125-26-077703
0001655050
Revenue and margins
Bain Capital Specialty Finance, Inc. had $273M of revenue in fiscal 2025, down 6.6% on the year before.
Net income and earnings per share
From fiscal 2020 to 2025, diluted EPS grew 61.3% a year. Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was — in fiscal 2025, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Bain Capital Specialty Finance, Inc. returned $146M to shareholders in fiscal 2025. The diluted share count rose 0.4%.
Balance sheet
Cash, debt and the ratios that show how comfortably Bain Capital Specialty Finance, Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $87.4M | $30.2M | $43.0M | $51.6M | $23.1M |
| Debt incl. finance leases | $1.4B | $1.4B | $1.3B | $1.4B | $1.5B |
| Debt / equity | 1.3x | 1.2x | 1.1x | 1.2x | 1.3x |
| Total assets | $2.6B | $2.6B | $2.5B | $2.6B | $2.7B |
| Total liabilities | $1.5B | $1.5B | $1.3B | $1.5B | $1.5B |
| Shareholders' equity | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B |
| Net debt (− = net cash) | $1.3B | $1.4B | $1.2B | $1.3B | $1.4B |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Net income is positive | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Cash from operations is positive | ✓ | ✓ | ✕ | ✓ | ✕ | ✓ |
| Return on assets rose | — | — | ✕ | ✓ | ✕ | ✕ |
| Cash from operations exceeds net income | ✓ | ✓ | ✕ | ✓ | ✕ | ✕ |
| Debt fell relative to assets | — | — | ✓ | ✓ | ✕ | ✕ |
| Current ratio rose | — | — | — | — | — | — |
| Share count didn't rise | — | ✕ | ✓ | ✓ | ✓ | ✕ |
| Gross margin rose | — | — | — | — | — | — |
| Revenue rose relative to assets | — | — | ✓ | ✓ | ✕ | ✕ |
| F-score | — / 3 | — / 4 | 4 / 7 | 7 / 7 | 2 / 7 | 2 / 7 |
| Accruals ratio | — | −5.7% | 16.4% | −3.8% | 5.7% | 2.6% |
| Altman Z'' | — | — | — | — | — | — |
6 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $194M | $197M | $220M | $298M | $293M | $273M |
| Interest expense | $63.3M | $51.3M | $52.3M | $80.0M | $74.7M | $80.6M |
| Income tax | — | — | $0.0M | $0.0M | $0.0M | — |
| Net income | $8.3M | $120M | $105M | $123M | $119M | $98.8M |
| Diluted EPS | $0.14 | $1.86 | $1.63 | $1.91 | $1.85 | $1.53 |
| Diluted shares | 0.06B | 0.06B | 0.06B | 0.06B | 0.06B | 0.06B |
| Cash flow | ||||||
| Cash from operations | $89.4M | $266M | −$317M | $219M | −$27.1M | $29.5M |
| Dividends paid | — | $87.8M | $87.8M | $99.4M | $114M | $146M |
| Dividends and buybacks | — | $87.8M | $87.8M | $99.4M | $114M | $146M |
| Balance sheet | ||||||
| Cash and short-term investments | $81.7M | $87.4M | $30.2M | $43.0M | $51.6M | $23.1M |
| Total debt | — | $1.4B | $1.4B | $1.3B | $1.4B | $1.5B |
| Total assets | — | $2.6B | $2.6B | $2.5B | $2.6B | $2.7B |
| Total liabilities | — | $1.5B | $1.5B | $1.3B | $1.5B | $1.5B |
| Shareholders' equity | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B |
| Margins | ||||||
| Net margin | 4.3% | 60.7% | 48.0% | 41.4% | 40.8% | 36.1% |
| Returns | ||||||
| Return on equity | 0.8% | 11.1% | 9.5% | 11.0% | 10.5% | 8.8% |
| Return on assets | — | 4.7% | 4.1% | 4.9% | 4.7% | 3.7% |
| Return on tangible equity | 0.8% | 10.9% | 9.4% | 10.9% | 10.5% | 8.8% |
| Growth | ||||||
| Revenue growth | — | 1.5% | 11.2% | 35.6% | −1.7% | −6.6% |
| Net income growth | — | 1,347.3% | −12.0% | 17.0% | −3.2% | −17.3% |
| EPS growth | — | 1,228.6% | −12.4% | 17.2% | −3.1% | −17.3% |
| Share count change | — | 10.0% | 0.0% | 0.0% | 0.0% | 0.4% |
| Financial health | ||||||
| Debt / equity | — | 1.3x | 1.2x | 1.1x | 1.2x | 1.3x |
| Quality scores | ||||||
| Piotroski F-score | — | — | 4.0 | 7.0 | 2.0 | 2.0 |
| Accruals ratio | — | −5.7% | 16.4% | −3.8% | 5.7% | 2.6% |
Source: SEC EDGAR XBRL filings (CIK 0001655050). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.
